Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is considered, most common cause of end stage Liver disorder needing liver transplantation worldwide. NAFLD is considered the hepatic presentation of metabolic syndrome. The association between thyroid dysfunction and NAFLD has increasingly become a focus of research.
Introduction
OBESITY is considered a worldwide health problem and its prevalence is known to increase steadily and dramatically all over the world. In parallel with epidemic obesity, Non-Alcoholic Fatty Liver Disease (NAFLD) has also been increasingly recognized worldwide in the last decade [1] .
High Body Mass Index (BMI) is associated with the development of cardiovascular risk factors such as Hypertension (HTN), dyslipidemia, insulin resistance, and Diabetes Mellitus (DM) [2] .
NAFLD is a rapidly growing diagnosis, and it is the most common cause of abnormal liver function tests worldwide [3] . The growing pattern of NAFLD prevalence is generally attributed to a global increase in the prevalence of obesity and other metabolic risk factors [4] .
NAFLD encompasses a histological spectrum from isolated hepatic steatosis to steatosis with inflammation, cell injury and possible fibrosis. Some cases may progress to cirrhosis, portal hypertension and consequently, to liver-related death in early adulthood [5] .
As the development of NAFLD and NASH (non-alcoholic steatohepatitis) may play a major role in determining the risk for type 2 diabetes and associated metabolic disease, there has been considerable scientific interest in identifying potential risk factors and surrogate markers for NAFLD in recent years [6] .
Thyroid hormone status is a key regulator of energy metabolism, while adverse alterations of 3267 3268 Evaluation of Thyroid Function in Obese Adults with NAFLD body composition, lipid status, cardiac function/ blood pressure and various nontraditional cardiovascular risk factors are associated with various degrees of thyroid dysfunction, ranging from subclinical to overt hypothyroidism [7] .
Elevated levels of Thyroid Stimulating Hormone (TSH) are a common finding in populations of obese adolescents [8] . At present, it remains less clear as to whether the frequently observed increase in TSH level is a secondary consequence of obesity or whether it has an independent role in the pathogenesis of obesity, dyslipidemia and insulin resistance [8] .
The studies were conflicting about the association between thyroid abnormalities and NAFLD. Although thyroid dysfunction mainly in the form of hypothyroidism and subclinical hypothyroidism has been reported in NAFLD, other studies did not show any significant correlation between hypothyroidism, and thyroid autoimmunity and NAFLD. However, the latter issue is relatively a new area of investigation that requires much more studies.
Patients and Methods

Patients of the study:
The present study included obese with Non-Alcoholic Fatty Liver (NAFLD) patients and patients obese without NAFLD recruited from endocrinology, diabetes and metabolism outpatient clinics and inpatient wards, Internal Medicine Department in Tanta University Hospitals and the other 60 were obese non NAFLD from July 2017 to February 2018 (six months period). Obesity was confirmed as BMI was more than 30kg/m 2 .
Study design: Cross sectional study.
Inclusion criteria: Patients included in the obese groups were:
Obese patients with BMI more than 30 with NAFLD with three degrees of obesity (mild, moderate and severe) were established on the basis of BMI cut-off points of 30-34.9, 35-39.9 and more than 40kg/m 2 , respectively, from both gender (malefemale) and patients with non-alcoholic liver disease.
Exclusion criteria:
Patients with hypothyroidism or hyperthyroidism, patients receiving any anti thyroid drugs or thyroid hormones, diabetic patients, patients with alcohol consumption, pregnancy and breast feeding, patients with chronic kidney and liver disease (viral (A-C-B-E), autoimmune, inherited and drug induced), patients with surgeries that lead to secondary NAFLD as gastropexy, small bowel resection, jejunal bypass and biliopancreatic diversion, patients taking any drugs that affect liver and thyroid function as corticosteroid, valproate, amiodarone, autoimmune hepatitis or inherited liver disease as alpha-one antitrypsin deficiency, Wilson disease and hemochromatosis and females taking contraceptive pills or using hormonal IUDs.
Study approval: Permission obtained from the Research Ethics Committee as a part of the Quality Assurance Unit in the Faculty of Medicine Tanta
University. An informed written consent was obtained from all participants in this research.
Study design:
Our study patients were classified into 2 groups: • Group 1: Includes 60 obese with Non-Alcoholic Fatty Liver (NAFLD) patients.
• Group 2: Includes 60 obese non NAFLD patients.
All patients included in this study were subjected to: Through history taking, complete physical examination, measurement of BMI, waist circumference, hip circumference and W/H ratio.
Blood sampling and laboratory investigation:
Blood samples obtained for routine laboratory investigation like Serum total cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Low-Density Lipoprotein Cholesterol (LDL-C) and Triglycerides (TG), Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), y-Glutamyl Transferase (GGT) ,serum albumin, complete blood count, fasting blood glucose level, fasting insulin level for (HOMA-IR) and virology (HBVs Ag, HCV Ab).
Also specific laboratory investigations were done like serum Thyroid Stimulating Hormone (TSH), Free thyroxin (FT4), Free Tri-iodiothyronine (FT3) by ELISA, Anti thyroid peroxidase (ANTI-TPO) and Anti thyroglobulin (Tg Ab).
Radiological investigations:
Abdominal ultrasound to detect fatty liver, Thyroid ultrasound is typically used to analyze the appearance of thyroid nodules according to the British Thyroid Association and determine if thyroid nodules are benign or have features that require biopsy were both done for all our patients.
NAFLD fibrosis score:
NAFLD fibrosis score is based on six readily available variables (i.e. age, Body Mass Index (BMI), hyperglycemia, platelet count, albumin, and AST: ALT ratio) and is recognized as a clinically useful tool to identify NAFLD patients with a higher likelihood of having bridging fibrosis and/or cirrhosis was done for all our patients.
Statistical analysis:
The quantitative variables were presented as a mean ± Standard Deviation (SD) and compared by t-test in case those variables are normally distributed and by Mann-Whitney U-test in case that they are not normally distributed. The categorical variables were statistically analyzed by the chisquare test. SPSS 25.0 software was used for analysis and p-values equal to or less than 0.05 were considered significant.
Results
Regarding gender characters of study participants showed that, the female represented the majority of participants by 69.2% with more prevalent in NAFLD female group by 75% than non-NAFLD 63.3% with p-value=0.166. There is no age specification between obese NAFLD and obese non-NAFLD groups as mean are (49.70 ±4.12), (48.90±7.40) respectively in the two groups with p=0.466 as shown in (Table 1) . Chi-square:
Results of ( Table 2) revealed that, BMI results of studied participants show that the mean of BMI in obese participants NAFLD is 36.37 ±3.44 and 35.15 ±3.21 for obese participants non-NAFLD with statistically significant results in between both being higher in NAFLD group (p=0.048*). WC results of studied participants show that the mean of WC in obese participants NAFLD is 121.38±8.70 and 119.65±6.74 for obese participants non -NAFLD with statistically no significant results in between both (p=0.225). There is no significant difference between both groups regard W/H ratio (p=0.104), mean of W/H ratio of both groups obese NAFLD and obese non-NAFLD (0.95 ±0.06cm and 0.93±0.05cm respectively).
As regard ALT, there is significant difference between obese NAFLD and obese non-NAFLD with mean values 29.12 ± 11.10, 21.40±6.20 respectively (p=0.001) higher in NAFLD group. Also AST results showed significant difference in both groups (p=0.001) with mean values in obese NAFLD group 30.72 ± 11.78 and 22.85 ± 6.55 for obese non-NAFLD group.
Additionally results of ( (Table 3) . As regard thyroid ultrasound there is no significant difference between NAFLD and non-NAFLD group as all patients had normal ultrasound except 4 patients in NAFLD group have thyroid nodules as presented in (Table 5 ).
As shown in (Table 6 ); BMI and WC were significant positively correlated with TSH (p= 0.043*, r=0.262), (p=0.047*, r=0.253) respectively, WC showed significant negatively correlated with FT4 (p= 0.00 1 *, r=-0.510). In non-NAFLD group were significant positively correlated with TSH (r=0.534, p=0.001 *), (r=0.379, p=0.003 *) respectively and both significant negatively correlated with FT4 (r=-0.298, p=0.048*), ( r=-0.287, p= .0.026*) respectively. 
Discussion
In parallel with epidemic obesity, Non-Alcoholic Fatty Liver Disease (NAFLD) has also been increasingly recognized worldwide in the last decade [9] . Over the past decade, beginning with a study by Liangpunsakul S et al., 2003 [10] , the association between thyroid dysfunction and Non-Alcoholic Fatty Liver Disease (NAFLD) has increasingly become a focus of research.
Data of the current study demonstrated that there was significant difference between obese NAFLD and obese non-NAFLD group in anthropometric measurement of obesity as significant increase in BMI in NAFLD group than non-NAFLD group. That was in agreement with Giogro B et al., 2005 that found that BMI is an independent predictor of NAFLD [11] .
Also Giogro B et al., 2005, stated that a large waist as identified by the operational definition of the metabolic syndrome, was not an independent predictor of NAFLD in agreement with our study as WC was not elevated in NAFLD obese group over non-NAFLD obese group [11] .
Waist circumference is a surrogate marker of visceral adiposity and a risk factor for cardiovascular and metabolic disease [12, 13] .
Also Qing Pang et al., 2015 stated that high BMI independently associated with NAFLD, in agreement with our study but also stated that high WC associated with increase in the NAFLD incidence rate against our study [14] .
Body mass index and WC have been considered as predictors of NAFLD severity according to Rocha R et al., 2005 [15] . Supporting our data a chinese study Shou-Wu Lee et al., 2016 stated that BMI, and not WC, had a strong positive association with NAFLD. Patients with higher BMI and higher WC had additional risk for NAFLD [16] .
Also, there was significant increase in level of ALT, AST in obese NAFLD group than in obese non-NAFLD group and there is no significant difference between the two groups as regard GGT level. This is supported by Dowman JK et al., 2010 that stated that non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes (ALT, AST) [17] .
By contrast to our study Pouneh M et al., 2003 the entire histologic spectrum of NAFLD can be seen in individuals with normal ALT values [18] .
As regard to HOMA IR, we found that it was significantly higher in obese NAFLD group than obese non-NAFLD, similar results were obtained by Adel A et al., 2012 that clarified that HOMA-IR was a significant independent predictor of the grade of steatosis and stage of fibrosis [19] .
In our study, there was no significant difference in TC levels between obese NAFLD, obese non-NAFLD group. While there is significant increase in the level of TG, LDL-C in obese NAFLD than obese non-NAFLD group, HDL-C levels show significant decrease in NAFLD group than non-NAFLD group.
Our study is supported by Muhammad W et al., 2017 that who stated that dyslipidemia in nonalcoholic fatty liver disease in form of atherogenic dyslipidemia characterized by high LDL-C levels, low HDL-C levels and hypertriglyceridemia [20] . In NAFLD, this intrahepatic lipid accumulation can be explained from lipid metabolism abnormalities such as increased whole body lipolysis, liver Free Fatty Acid (FFA) uptake and Very Low Density Lipoprotein (VLDL) synthesis as well as reduced FFA oxidation and Triglycerides (TG) export [24] .
These alterations in lipid metabolism are linked to an induction of inflammation and oxidative stress as well as to abnormal adipokine (such as leptin, adiponectin, resistin, and retinol binding protein-4) production that affect signaling pathways [25, 26] .
In our study, there was significant difference between both obese groups NAFLD, non-NAFLD as regard TSH levels as in NAFLD group there is elevation of TSH within normal range (0.4-4.2mIU /L (milli international units per liter) for adult about 39 patient with NAFLD have TSH level <2.7mIU /L, as compared with obese non-NAFLD group. Only one patient reported subclinical hypothyroidism with TSH level 5.2mIU/L and normal FT3, FT4.
Also FT4 results show statistically significant difference lower within normal range in obese NAFLD group than obese non-NAFLD group. FT3 results there are no significant difference between two groups. Thyroid function tests were within normal range in all groups.
Our study supported by Jiaoyue Z et al., 2012 study that found high normal value of TSH had relation to obesity and NAFLD and females and males with NAFLD had a significantly higher normal level of TSH than those non-NAFLD [27] .
In agreement with our study Carolina C et al., 2017 stated that the association between TSH levels within the reference range and NAFLD seems to be mediated by metabolic syndrome criteria [28] . Also Lucia C et al., 2013 results with our study stated that high-though normal TSH independently predict NASH [29] . The same Moustafa et al., 2009 cleared that serum TSH level in NASH patients was higher than healthy controls (2.1 ±0.75µ IU/mL vs. 1.75±0.9µ IU/mL) within normal range [30] .
As regard FT4 as in our study Ulla L et al., 2015 stated a significant inverse association between the FT4 concentration of NAFLD could be demonstrated, while no significant association could be identified for FT3 or TSH [31] .
By contrast, the FT3 concentration, both in Ulla L et al., 2015 and in those of Ittermann et al., 2012 and Xu et al., 2011, had no identified value as a marker for NAFLD as the present study [31] [32] [33] .
In contrast to our data some studies included in Ahad E et al., 2014, reported growing data about higher prevalence of thyroid dysfunction in the form of overt or subclinical hypothyroidism among patients with NAFLD/NASH [34] , Like Pagadala et al., 2012 reported that hypothyroidism was more common in patients with NASH compared to patients with NAFLD [35] .
Chen Y et al., 2018 achinese study reported that the status of metabolic disorders like obesity and NAFLD might be associated with higher risks of TN in both genders. In women, obesity, central obesity, and NAFLD might contribute to the development of a taller-than-wide thyroid nodule, against with the present study [36] .
As regard thyroid antibodies ANTI-TPO and Tg Ab there is no significant difference between NAFLD and Non-NAFLD groups. With the present study Eshraghian et al., 2013 reported that no association between thyroid autoimmunity and NAFLD like our study as regard ANTI-TPO and Tg Ab [37] .
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